Understanding Inflammatory Bowel Disease and Its Recurrences

For those dealing with inflammatory bowel disease (IBD), it’s not uncommon to feel better on treatment only to experience a flare-up later on. This can be frustrating, especially when you’ve gotten used to a more manageable state.

Researchers suggest that even when symptoms like abdominal pain and diarrhea are controlled, some intestinal cells may remain weak and prone to issues.

The two primary types of IBD are Crohn’s disease and ulcerative colitis. Both involve a long-term inflammation of the digestive tract, which can be quite debilitating.

While treatments can lead to periods of remission—those times when the disease seems less active—another flare can occur unexpectedly.

In a recent study, scientists observed abnormal cell death in intestinal tissue samples from patients whose conditions were, well, under control. This finding might explain why some people still struggle with the disease despite a lack of noticeable symptoms.

Britt Christensen, a gastroenterologist and head of the Inflammatory Bowel Disease Unit at the Royal Melbourne Hospital, mentioned that the bowel could retain vulnerabilities that don’t show up as typical symptoms.

Published in Science, the study analyzed over 900 biopsies from 80 individuals, including both those with and without IBD. Interestingly, many IBD patients had either inactive or mildly active forms of the disease.

Led by researchers from Australia’s Walter and Eliza Hall Institute, the team focused on studying the intestinal lining, which is critical for protection and has a remarkable capacity for renewal.

Usually, controlled cell death is a way to get rid of unwanted or damaged cells, while stem cells are there to take their place. However, the study showed that inflammation could alter the way intestinal cells behave, leading to a higher susceptibility to abnormal death signals.

Worryingly, some of these signals were even found in tissues without overt inflammation, suggesting that problems might linger beneath what appears to be a healthy surface.

Christensen elaborated, saying this indicates that just because a patient is in clinical remission doesn’t truly mean the biological processes have completely returned to normal.

To delve deeper, the researchers cultivated miniaturized intestinal tissues derived from human samples, termed organoids, allowing them to observe how cells react to inflammation. Other studies have also harnessed human cells to recreate aspects of IBD on microchips.

The lab experiments unveiled a surprising link between different processes of cell death. The tissue from patients revealed signals of necroptosis—a form of cell death that can cause cells to rupture and release inflammatory contents. Yet, in organoids exposed to inflammatory cues, the primary mode of cell death was notably apoptosis, a more structured form.

What’s even more interesting is that blocking necroptosis didn’t stop cell death in the scenarios they tested. Which raises questions about whether drugs that target these signals in diseased tissues are sufficient on their own to safeguard cells.

Some experiments showed that deleting certain genes could protect specific cell types, but more investigation is necessary to assess if these approaches can be safely applied to patients.

The team also looked into whether the observed cellular changes were linked to future flare-ups. Among 52 IBD patients, about 30 had follow-up information for two to three years. Out of these, 16 experienced a flare that needed more intensive treatment, while 14 remained stable. Yet, 22 patients were lost to follow-up.

The relapsed patients had higher levels of a particular cell-death signaling marker compared to those without IBD. Still, this doesn’t definitively indicate that this marker can predict who will experience a relapse.

Those who did relapse also displayed more significant microscopic inflammation at the outset. If larger studies were conducted, they might clarify whether these signals offer valuable insights beyond current inflammation assessments.

Christensen did note that while the follow-up findings are intriguing, they’re still in the early stages.

Currently, these findings might illuminate why flare-ups keep occurring, but they are not a reliable test for predicting them.

“Protecting the lining and its ability to regenerate could complement treatments aimed at managing inflammation,” she suggested.

That being said, pathways involved in cell death play vital roles, such as eliminating damaged or potentially cancerous cells.

Christensen emphasized, “We haven’t demonstrated that blocking these mechanisms can safely prevent flares in patients.”

Looking ahead, the goal is what she refers to as “molecular healing”—addressing the underlying cellular issues that persist even after recovery seems apparent. Whether this approach can help patients maintain their wellness longer is still to be determined.

The research has been published in Science.